NCT02028494: Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer

NCT02028494
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active unstable central nervous system metastases that require treatment
https://ClinicalTrials.gov/show/NCT02028494

Comments are closed.

Up ↑